1. Introduction {#sec1-jcm-07-00248}
===============

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia with an increasing trend of prevalence following widespread population aging \[[@B1-jcm-07-00248]\]. It is estimated that AF currently affects around 2.3 million adults in the United States, and the number of affected people is projected to increase to 5.6--15.9 million by 2050 \[[@B1-jcm-07-00248]\]. AF has a significant effect on cardiovascular events including stroke, peripheral embolization, and associated morbidities and mortalities \[[@B1-jcm-07-00248]\]. The existence of AF is independently associated with the risk of the development and severity of acute kidney injury (AKI) in both surgical and medical settings \[[@B2-jcm-07-00248]\].

Recent studies suggest that AKI episodes are associated with a higher risk of developing cardiovascular events and overall mortality \[[@B3-jcm-07-00248],[@B4-jcm-07-00248],[@B5-jcm-07-00248]\]. Nevertheless, the influence of AKI on subsequent incident AF has not been fully addressed in previous research. Most investigations only evaluate the concurrent occurrence of AKI and AF in a limited number of patients undergoing cardiac surgeries within a relatively short follow-up period \[[@B6-jcm-07-00248],[@B7-jcm-07-00248]\]. In these studies, the development of postoperative AKI was found as an independent factor associated with the new-onset postoperative AF \[[@B6-jcm-07-00248],[@B7-jcm-07-00248]\]. In line with these interpretations, new-onset AF after AKI in a nationwide survey for an extended followed-up period is necessary \[[@B7-jcm-07-00248],[@B8-jcm-07-00248],[@B9-jcm-07-00248],[@B10-jcm-07-00248]\]. In particular, the National Institute for Health and Clinical Excellence (NICE) guideline raises an ultimate critical point: if the development of AF occurs, the assessment to evaluate the risk of having a stroke is necessary. However, little information is available regarding cardiovascular events and outcomes after new-onset AF in this subset.

A proper understanding of the risk factors associated with kidney disease and AF development may allow primary care physicians to initiate preventive strategies and thereby potentially decrease the risk of AF. Thus, we conducted this study aiming to test the hypothesis that the occurrence of dialysis-requiring AKI (AKI-D), as well as the "recovery pattern" of the AKI, would increase the subsequent risk of subsequent AF and result in worse cardiovascular injury.

2. Materials and Methods {#sec2-jcm-07-00248}
========================

2.1. Data Source {#sec2dot1-jcm-07-00248}
----------------

This retrospective population-based cohort study was conducted using the data of Taiwan's National Health Insurance Research Database (NHIRD) in the period from 1 January 2000 to 3 December 2010. The NHIRD is an encrypted database released by the National Health Research Institutes (NHRI) for research purposes. The NHIRD includes all information on outpatient visits, hospital admissions, prescriptions, interventional procedures, disease profiles, and vital status of the National Health Insurance (NHI) program which provides comprehensive medical care covering more than 99% of the country's population of 23 million people. The baseline comorbidities were identified from at least three outpatient visits or one inpatient claim within one year preceding the index hospitalization with the first dialysis. This identification method has been well validated with adequate predictive power \[[@B3-jcm-07-00248]\]. The Charlson Comorbidity Index (CCI) was calculated by weighting baseline comorbidities.

For confidentiality purposes, identification numbers were encrypted before being released for research, but the uniqueness of the encrypted identification is retained to ensure valid internal linkage. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki. The study was approved by the institutional review board of the National Taiwan University Hospital (201212021RINC), and informed consent was waived since all personal data were de-identified in the database to protect privacy.

2.2. Study Cohort and Design {#sec2dot2-jcm-07-00248}
----------------------------

This study included patients aged 18 to 100 years without a history of AF, mitral valve disease, and hyperthyroidism for at least one year preceding study enrollment, and who developed de novo AKI-D during their index hospitalization and survived to at least 30 days after discharge.

Disease diagnoses were classified according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). AKI-D was defined by ICD-9 codes for AKI (584.3, 634.3, 635.3, 636.3, 637.3, 638.3, 639.3, 669.3, or 958.5) along with procedure codes for acute dialysis. CKD was defined by ICD-9 codes for CKD (580, 580.x, 584.x, 586, 399.5). Advanced CKD was defined as CKD patients with concomitant erythropoiesis-stimulating agents \[[@B3-jcm-07-00248]\]. The diagnosis accuracy of AKI and chronic kidney disease (CKD) by ICD-9-CM, as well as the definition of advanced CKD, were detailed in [Supplementary File 1](#app1-jcm-07-00248){ref-type="app"}.

Renal function recovery was defined by withdrawal from dialysis before the 31st day after discharge. The patients who had successfully withdrawn from dialysis within hospitalization or within the 30-day period after hospital discharge were categorized into "AKI-recovery" group, while those had not withdrawn from dialysis within the 30-day period were categorized in "non-recovery" group. In an attempt to make a less biased comparison, we further constructed a control group which contained patients without AKI and who survived to discharge from the remaining hospitalized patients (non-AKI group).

2.3. Research Variables {#sec2dot3-jcm-07-00248}
-----------------------

The demographic data including age, gender, monthly income, hospital levels, baseline comorbidities, CHA2DS2-VASc scores before discharge, the frequency of outpatient visits and medications within one year following discharge, and the patients' outcomes were identified and analyzed.

2.4. Outcome Variables {#sec2dot4-jcm-07-00248}
----------------------

Our primary outcome was de novo AF development (ICD-9-CM code 427.31) after hospital discharge. To ensure the accuracy of the AF identification, the diagnosis of AF needed to be confirmed by a doctor, or doctors, and recorded in the diagnosis list of the chart more than twice in outpatient visits, or recorded in the discharge diagnosis list more than once in an inpatient setting. The diagnostic accuracy of AF based on the ICD-9-CM codes has been previously validated \[[@B11-jcm-07-00248],[@B12-jcm-07-00248],[@B13-jcm-07-00248]\]. The secondary outcomes included major adverse cardiac event (MACE), ischemic stroke (ICD-9-CM code 433.x, 434.x, or 436), and hemorrhage stroke (ICD-9-CM code 431 or 432). MACE was defined as coronary artery disease-related death, nonfatal myocardial infarction, angina, and revascularizations.

We evaluated the influences of AKI-D on the risk of subsequent incident AF in the whole study population as well as in different subgroups. Furthermore, besides testing the association between AKI-D and these outcomes, we also evaluated the association between AF and the above-mentioned secondary outcomes. All enrolled patients were followed from the date of index hospital discharge to the first diagnosed outcomes and were censored at death unrelated to coronary artery disease, or at the end of the study (31 December 2010).

2.5. Statistical Analysis {#sec2dot5-jcm-07-00248}
-------------------------

Statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC, USA). A two-sided *p*-value of ≤ 0.05 was considered statistically significant. Continuous variables were presented as the mean ± standard deviation (SD), and categorical variables were described as counts (percentages). The propensity scores were determined by multivariate logistic regression analysis. The Cox proportional hazard model was applied to examine the effect of non-recovery and AKI-recovery groups on subsequent AF development, as well as the influence of AF on other major adverse events. Because withdrawal from dialysis is likely to adhere to the condition of acute kidney disease, advanced CKD was identified to be a time-varying covariate \[[@B3-jcm-07-00248],[@B14-jcm-07-00248]\].

By using the propensity score matching method, we proposed three matched groups (non-recovery group: AKI-recovery group: non-AKI group) on a 1:1:2 ratio. The propensity scores, containing the baseline characteristics and risk factors listed in [Table 1](#jcm-07-00248-t001){ref-type="table"}, were calculated by multivariate logistic regression.

Several demographic factors were adjusted in the hazard models to evaluate the impact of AKI on AF, as well as the influence of incident AF to other adverse events. Variable selection was performed using stepwise multiple regression methods, with both *p*-to-enter and *p*-to-leave equal to 0.15. Final results of multivariate analyses were presented by hazard ratio (HR) and adjusted HR (aHR) with 95% confidence interval (CI). To exclude the confounding effect of subsequent impaired renal function and the influence of chronic dialysis, we additionally took "advanced CKD" as a "time-varying covariate" in the Cox proportional hazard model determining the adjusted risk for subsequent AF.

3. Results {#sec3-jcm-07-00248}
==========

3.1. Characteristics of the Three Groups {#sec3dot1-jcm-07-00248}
----------------------------------------

From the period of 1 January 2000, to 31 December 2010, a total of 10,091 AKI-D patients were eligible for inclusion. Among them, 5284 patients withdrew from dialysis for at least 30 days, but 4807 patients did not. After the exclusion and sampling processes, a total of 10,450 patients without AKI and who survived to hospital discharge were enrolled as control group. After propensity score matching on a 1:1:2 ratio, we categorized these patients into non-recovery (*n* = 2895), AKI-recovery (*n* = 2895) and non-AKI (*n* = 5790) groups ([Figure 1](#jcm-07-00248-f001){ref-type="fig"}).

The follow-up period of the whole post-matching cohort was 6.38 ± 3.83 years (median, 6.68 years; range, 0.02--10.99 years). Among the three groups, the non-AKI group was the oldest. While the gender, socioeconomic status, baseline comorbidities, as well as outpatient follow-up visits and medication status were not statistically different among the three groups ([Table 1](#jcm-07-00248-t001){ref-type="table"}). All primary outcome (AF, *p* = 0.002) and secondary outcomes (MACE, ischemic stroke, hemorrhage stroke and all stroke, all *p* ≤ 0.001) were of statistical significance among the three groups ([Table 2](#jcm-07-00248-t002){ref-type="table"}).

3.2. Risk of Incident Atrial Fibrillation {#sec3dot2-jcm-07-00248}
-----------------------------------------

The occurrence time of AF since discharge was 3.24 ± 2.94 years (median, 0.24 years; range, 0.02--10.94 years). The incidence rates of AF were 0.94%, 1.14%, and 1.34% before propensity score matching in "non-AKI group", "AKI-recovery group", and "non-recovery group", respectively.

After propensity score matching, the adjusted risks for subsequent de novo AF development were significantly higher in both the "non-recovery group" (aHR = 1.62; 95% CI, 1.36--1.94; *p* ≤ 0.001) and the "AKI-recovery group" (aHR = 1.30; 95% CI, 1.07--1.58; *p* ≤ 0.01) compared to the "Non-AKI group" ([Table 3](#jcm-07-00248-t003){ref-type="table"} and [Figure 2](#jcm-07-00248-f002){ref-type="fig"}). When compared with "non-recovery group", the "AKI-recovery group" had a significantly lower risk of subsequent AF (aHR = 0.80; 95% CI, 0.616--0.933; *p* ≤ 0.01).

3.3. Risk of Incident Atrial Fibrillation in Subgroups {#sec3dot3-jcm-07-00248}
------------------------------------------------------

In the subgroup comparison, we found that "AKI-recovery group" has a significantly higher risk of incident AF than the "non-AKI group" in some subgroups. These subgroups included the patients without congestive heart failure (CHF) (aHR = 1.23; 95% CI, 1.06--1.42) and chronic obstructive pulmonary disease (aHR = 1.18; 95% CI, 1.01--1.36), those with CKD (aHR = 1.37; 95% CI, 1.05--1.80) and diabetes mellitus (aHR = 1.37; 95% CI, 1.05--1.79), as well as those receiving angiotensin-converting-enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) (aHR = 1.27; 95% CI, 1.04--1.54) and beta-blocker (aHR = 1.49; 95% CI, 1.24--1.80). Additionally, the subgroups who received anticoagulants (aHR = 1.23; 95% CI, 1.00--1.51) had marginally significant increased risks of AF ([Figure 3](#jcm-07-00248-f003){ref-type="fig"}).

3.4. Risk of Major Adverse Events between Patients with and without Incident Atrial Fibrillation {#sec3dot4-jcm-07-00248}
------------------------------------------------------------------------------------------------

After propensity score matching, the patients with de novo AF augmented risks for MACE (aHR = 2.11; 95% CI, 1.83--2.43), ischemic stroke (aHR = 1.33; 95% CI, 1.19--1.49) and all stroke (aHR = 1.28; 95% CI, 1.15--1.43) (all *p* ≤ 0.001) ([Table 4](#jcm-07-00248-t004){ref-type="table"}).

4. Discussion {#sec4-jcm-07-00248}
=============

This study is the first to demonstrate a long-term association between AKI and the subsequent incident AF in critically ill patients using a large nationwide cohort. We found that the experience of severe AKI necessitating dialysis, even in the patients who only required temporary dialysis, was associated with increased risk of subsequent incident AF. Moreover, the experience of incident AF further carried a higher risk of MACE, and ischemic stroke in these patients. Since AKI carries an increased risk of coronary events \[[@B3-jcm-07-00248]\], the increased AF following AKI could at least partially explain the elevated probability of MACE after AKI. Since the current study was designed using a selected population set from a nationwide database to evaluate the influence of AKI-D on the incident AF, the incidence rate of AF in this study was not comparable to other investigations \[[@B15-jcm-07-00248],[@B16-jcm-07-00248]\] for an epidemiological purpose.

Most of the previous studies evaluating the association between AF and AKI were designed with a relatively short study period using patients who underwent cardiac surgeries \[[@B6-jcm-07-00248],[@B7-jcm-07-00248]\]. One such study enrolled 446 cardiac surgical patients and found that the development of postoperative AKI was an independent factor associated with new-onset AF \[[@B6-jcm-07-00248]\]. Another prospective study including 2572 cardiac surgical patients disclosed that the occurrence of postoperative AKI carried the 1.7-fold increased risk of developing postoperative AF \[[@B7-jcm-07-00248]\]. In the subgroup comparison of the current study, although insufficient case numbers made the results not statistically significant, we also observed a tendency that patients receiving cardiac surgeries had a higher risk of incident AF than those without (aHR, 1.35 versus 1.14) ([Figure 3](#jcm-07-00248-f003){ref-type="fig"}). Nevertheless, the results from post-cardiac surgical patients probably could not be extensively applied to other patient settings, because the cardiac surgical patient is a special population with a higher risk of AF due to the relevant involvement of heart structurally and electrically \[[@B8-jcm-07-00248],[@B17-jcm-07-00248]\]. Furthermore, the temporal association between AKI and AF was difficult to be clarified by these studies because of a short period of observation \[[@B7-jcm-07-00248],[@B9-jcm-07-00248],[@B10-jcm-07-00248]\]. Compared to the previous studies, the clarified temporal association between in-hospital AKI and new-onset AF after hospital discharge, along with the long-term follow-up period in the current study, provides more strengthened evidence in this field.

In particular, we provide an important outcome estimate: that is, even after being adjusted with progression to subsequent advanced CKD or ESRD, in the worst of circumstances, AKI still independently contributes to subsequent incident AF or all-cause mortality. Therefore, the risk factors of the kidney injury that had engendered an AKI event may persist and eventually lead to future AF without direct causal association to the subsequent CKD.

4.1. Acute Kidney Injury and Atrial Fibrillation {#sec4dot1-jcm-07-00248}
------------------------------------------------

An increasing body of evidence has shown that AKI is independently associated with the occurrence of AF \[[@B18-jcm-07-00248]\]. AKI causes "remote organ injury" in the heart by the "classical" acute uremic effect, the inflammatory state and the modulating effect of the underlying morbidities associated with the injured kidneys, as well as the health care dilemma \[[@B5-jcm-07-00248]\].

Several mechanisms are proposed for explaining the association between AKI and the elevated risk of AF: (1) The increased preload because of the AKI-induced salt and water retention at the acute stage could increase the cardiac structural change \[[@B19-jcm-07-00248],[@B20-jcm-07-00248],[@B21-jcm-07-00248],[@B22-jcm-07-00248]\]. (2) The myocardial damage and impaired left ventricular function secondary to the enhanced neutrophil trafficking, endothelial dysfunction, myocyte apoptosis, as well as an increased level of inflammatory cytokines \[[@B19-jcm-07-00248],[@B20-jcm-07-00248],[@B21-jcm-07-00248],[@B22-jcm-07-00248]\]. Additionally, fibroblast growth factor 23 (FGF-23), a biomarker for predicting early AKI presentation and cardiovascular morbidity and mortality \[[@B23-jcm-07-00248]\], is disclosed to have markedly elevated serum level in patients with AKI. Higher FGF-23 levels were also found to be associated with elevated risk of AF development in both patients with and without clinical cardiovascular disease \[[@B24-jcm-07-00248]\]. Thus, the enhanced AF incidence might be attributed to the atrial remodeling related to increased FGF-23 levels \[[@B25-jcm-07-00248]\]. Taken together, these results provide a new perspective on the pathogenesis of sinoatrial dysfunction after AKI and open new avenues for treatment of the disease. (3) The activation of the sympathetic nervous system: previous studies have demonstrated that ischemia-reperfusion injury related AKI would activate a sympathetic reflex \[[@B26-jcm-07-00248]\]. The activating sympathetic activation of the atrium would subsequently cause remodeling of the cardiac autonomic neural tissue and promote further persistence and recurrence of AF \[[@B27-jcm-07-00248]\].

Of note, in the subgroup of "patients without CHF", the finding that "recovery AKI-D patients had a higher risk of subsequent AF than non-AKI patients" was consistent with the results from our whole study population. This was reasonable when we considered this finding as a result without the confounding the effect of CHF. Nevertheless, diverse observations were disclosed in patients with CHF. In these patients, the indication of dialysis could more likely be "fluid overload", which was associated with a more favorable prognosis than other indications. On the contrary, the mortality risk might be higher in patients with more severe AKI-D and CHF than those who only had AKI-D. Owing to the lack of the etiology and severity of congestive heart failure, and the indication of dialysis in the database for further analysis, the observation among patients with CHF should be inconclusive ([Figure 3](#jcm-07-00248-f003){ref-type="fig"}).

Additionally, the results among the subgroups of "hypertensive patients taking beta-blocker and ACEI/ARB" were also consistent with the findings from the whole population. These findings could be interpreted as the beneficial effects of the aforementioned anti-hypertensive medications minimizing the other confounding effects of the underlying cardiovascular disease. In contrast, the influences of AKI-D on AF were blunted in the patients not taking beta-blockers and ACEI/ARB. In fact, this subgroup contains two patient groups (patients without hypertension, and hypertensive patients not taking beta-blocker or ACEI/ARB for treatment) with different prognostic characteristics. Without doing further analysis, we could not draw any conclusions regarding this issue ([Figure 3](#jcm-07-00248-f003){ref-type="fig"}).

4.2. Major Adverse Events Associated with Atrial Fibrillation {#sec4dot2-jcm-07-00248}
-------------------------------------------------------------

In the current study, incident AF was associated with several major adverse events ([Table 4](#jcm-07-00248-t004){ref-type="table"}). Similar findings were also demonstrated that the development of AKI-D was associated with increased risk of in-hospital mortality and adverse events among patients with AF \[[@B2-jcm-07-00248]\]. Following our results, patients who have AF and AKI will have a high incidence of cardiovascular events, especially coronary events and ischemic stroke. Distant organ injury, a direct consequence of deleterious systemic effects following AKI, is an important issue for clinical care \[[@B5-jcm-07-00248]\].

The association between AF and abnormal renal function is also an interesting and essential issue to be discussed. Among stable anticoagulated patients with AF, the presence of impaired baseline renal function was reported as an independent risk factor of the occurrence of thrombotic/vascular events, stroke, bleeding, and mortality \[[@B28-jcm-07-00248],[@B29-jcm-07-00248]\]. During the two-year follow-up period, about 21% to 32% of patients had a rapid renal function deterioration (decline of estimated Glomerular filtration rate (eGFR) \> 5--10 mL/min/1.73 m^2^) \[[@B28-jcm-07-00248],[@B30-jcm-07-00248]\]. More renal function deterioration in absolute levels (decreases of eGFR ≥ 15--25 mL/min/1.73 m^2^ within two years) or relative percentage (decline of ≥ 25% eGFR) within 2 years was independently associated with the occurrence of stroke or death in these patients \[[@B29-jcm-07-00248]\]. The independent risk factors for the development of severe kidney disease include diabetes, CHF, coronary artery disease and impaired baseline renal function \[[@B28-jcm-07-00248]\]. However, normal or near-normal baseline renal function did not exclude the subsequent development of severe renal impairment over time \[[@B28-jcm-07-00248]\].

Regarding the therapeutic strategy for AF, the old drug "Warfarin" is thought to be associated with higher risk for AKI, which is probably due to a higher risk of glomerular hemorrhage known as anticoagulation-related nephropathy \[[@B31-jcm-07-00248]\]. In a randomized study enrolling 18,113 patients, Bohm et al. \[[@B32-jcm-07-00248]\] found that patients receiving warfarin, as opposed to those receiving direct oral anticoagulants (DOAC), have more rapid eGFR decline after an average follow-up period of 30 months. Patients with poor international normalized ratio control (i.e., time in the therapeutic range \<65%) tend to have a faster decline in eGFR. Similarly, Chan et al. \[[@B33-jcm-07-00248]\] found that DOAC users had an overall 21% lower risk of AKI compared with warfarin users among Asians with nonvalvular AF. The beneficial effect was especially disclosed in among patients with eGFR \> 60 mL/min/1.73 m^2^.

As to the association between AF and MACE, some information should be addressed. In a prospective cohort of 23,928 participants without coronary artery disease conducted by Soliman et al. \[[@B34-jcm-07-00248]\], AF was associated with around two-fold elevated the risk of myocardial infarction within a 6.9 year (median 4.5 years) follow-up. Consistent findings were found in the study enrolling 4,608 participants by O'Neal et al. \[[@B35-jcm-07-00248]\]. Within the median follow-up period of 12.2 years, 17.3% participants developed myocardial infarction, and AF independently carried 1.7 folds increase the risk of myocardial infarction. The increased cardiovascular risk of AF was further confirmed by a systemic review and meta-analysis including 15 cohort studies. Another work also found that AF is associated with an elevated risk of CHF and all-cause mortality in patients regardless of having coronary artery disease, and additionally with an elevated risk of subsequent myocardial infarction in those without coronary artery disease \[[@B36-jcm-07-00248]\]. Of note, the influences of AF on increasing risk of cardiovascular events were more prominent in women than men and African-Americans than Caucasians \[[@B34-jcm-07-00248],[@B35-jcm-07-00248],[@B37-jcm-07-00248]\].

Despite receiving oral warfarin treatment, patients with AF still have a high rate of cardiovascular events, including fatal/nonfatal myocardial infarction, cardiac revascularization, and cardiovascular death. The independent predictors of cardiovascular events included age, smoking, history of cerebrovascular and cardiac events, metabolic syndrome, CHF, and male gender \[[@B38-jcm-07-00248]\].

The cardiovascular safety of oral anticoagulants has long been debated. By using a systemic review and meta-analysis, Tornyos et al., \[[@B39-jcm-07-00248]\] disclosed that most of the DOACs were of safer than warfarin regarding the risk of subsequent myocardial infarction. A very recent work by Lee et al. \[[@B40-jcm-07-00248]\] further exhibited a favorable effect of DOACs as compared to warfarin in reducing cardiac complications in AF. In the analysis using 31,739 patients, all DOACs were associated with lower risk of myocardial infarction than warfarin.

AKI is now considered a growing global health alert \[[@B41-jcm-07-00248]\]. These findings are noteworthy from the perspective of a clinician caring for an individual with dialysis-requiring AKI. Considerable growth in AKI epidemiology and improvements in post-hospitalization resource utilization \[[@B42-jcm-07-00248]\] allowed us to examine the impact of AKI on AF and identify a large vulnerable population with increased risk of cardiovascular events and all-cause mortality \[[@B3-jcm-07-00248],[@B4-jcm-07-00248]\].

4.3. Limitations {#sec4dot3-jcm-07-00248}
----------------

Several limitations are worth mentioning. First, the nature of the observational study is subject to bias. Second, the study using administrative data is potentially limited by unmeasured confounding. The epidemiological data, the etiology, and severity of AKI, the indication of dialysis initiation, as well as some known risk factors including alcohol abuse and body mass index, which may further provide meaningful information regarding the association with subsequent AF, are not available in such a nationwide insurance research database. Third, the primary outcome of the current study is "non-valvular AF". The observations accrued here might not be extrapolated to patients with "valvular AF". Fourth, the precision of the disease diagnoses based on ICD-9-CM may be a concern. Fifth, although we have taken "advanced CKD" as a covariate in the Cox model when evaluating the adjusted risk for subsequent AF, the confounding effect of subsequent impaired renal function and chronic dialysis could not be completely excluded. Sixth, the start point of the follow-up period is indeed arguable. Some confounding effect from acute dialysis may exist, which probably increases the risk of AF in "AKI-recovery group", if immediate period after discharge is included in the observation period. Nevertheless, changing the start point from "after discharge" to "the 31st day after discharge" decreases 11% AF events without changing the results of the current study.

However, despite widespread interest and extensive research on AF, our understanding of the etiology and pathogenesis of this disease process is still incomplete. As a result, there are no set primary preventive strategies in a place apart from general cardiac risk factor prevention goals. Our result seems intuitive that a better understanding of acute dialysis as the risk factors for AF would better prepare medical professionals to initially prevent or subsequently treat these patients and follow up with groups who could not wean from acute dialysis.

5. Conclusions {#sec5-jcm-07-00248}
==============

In this current nationwide cohort study, we found that the experience of severe AKI necessitating dialysis carries an increased risk of subsequent AF, even in those weaned from acute dialysis. Further study is needed to determine the mechanisms which link AKI and subsequent AF and to identify potentially modifiable risk factors to decrease the burden of AF and subsequent risk of major adverse events.

The study was partly based on data provided by the National Health Insurance Administration, Ministry of Health and Welfare, Taiwan. The interpretation and conclusions shown in this paper do not represent those of National Health Insurance Administration, Ministry of Health and Welfare, National Health Research Institutes, or the National Taiwan University Hospital. We also express our sincere gratitude to all staff of the Taiwan Clinical Trial Consortium, TCTC.

The following are available online at <http://www.mdpi.com/2077-0383/7/9/248/s1>, Supplementary File 1. Validation of AKI code by NSARF; Validation of CKD code by NSARF; Definition of advanced CKD.
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Click here for additional data file.
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![Study flow diagram. Abbreviations: AF, atrial fibrillation; MV, mitral valve; PDC, peritoneal dialysis catheter; VA, vascular access.](jcm-07-00248-g001){#jcm-07-00248-f001}

![Cumulative incidences of atrial fibrillation among the three groups. Note: The analysis was performed using the Cox proportional hazard method with adjustment to the Charlson Comorbidity Index, age, gender and advanced chronic kidney disease (time-varying covariate). \*\*\* denotes *p* \< 0.001, \*\* denotes *p* \< 0.01. Abbreviations: AF, atrial fibrillation; AKI, acute kidney injury.](jcm-07-00248-g002){#jcm-07-00248-f002}

![Subgroup comparisons for the risk of atrial fibrillation. Note: The forest plot for the comparison of AKI-recovery group versus non-AKI group was drawn using the before-matching population with adjustment to the Charlson Comorbidity Index, age, and gender. Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; AF, atrial fibrillation; AKI, acute kidney injury; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.](jcm-07-00248-g003){#jcm-07-00248-f003}

jcm-07-00248-t001_Table 1

###### 

Comparisons of the baseline characteristics among the three groups.

  ---------------------------------------------------------------------------------------------------------------------------------------------------
                                Before Matching\   After Matching\                                                                          
                                *n* = 20,540       *n* = 11,680                                                                             
  ----------------------------- ------------------ ----------------- --------------- --------- -------------- -------------- -------------- ---------
  Age, years                    59.7 ± 15.2        60.3 ± 17.7       59.8 ± 16.1     \<0.001   59.6 ± 15.7    60.2 ± 17.2    60.6 ± 15.7    0.01

  Gender, men                   2390 (49.7%)       3172 (60.0%)      5540 (53.0%)    \<0.001   1542 (53.3%)   1535 (53.0%)   3178 (54.9%)   0.68

  **Monthly income, NTD**                                                            \<0.001                                                0.21

  \<19,100                      1700 (35.4%)       2103 (39.8%)      3649 (34.9%)              1064 (36.8%)   1099 (38.0%)   2203 (38.1%)   

  19,100--41,999                2449 (51.0%)       2434 (46.1%)      5285 (50.6%)              1443 (49.8%)   1378 (47.6%)   2925 (50.5%)   

  ≥42,000                       658 (13.7%)        746 (14.1%)       1516 (14.5%)              388 (13.4%)    418 (14.4%)    762 (13.2%)    

  **Hospital level \***                                                              \<0.001                                                \<0.001

  Level 1                       1916 (39.9%)       2648 (50.1%)      4046 (38.7%)              1218 (42.1%)   1184 (40.9%)   2641 (45.6%)   

  Level 2                       2092 (43.5%)       2158 (40.84%)     3972 (38.0%)              1249 (43.1%)   1340 (46.3%)   2282 (39.4%)   

  Levels 3 + 4                  799 (16.6%)        477 (9.0%)        2,432 (23.3%)             428 (14.8%)    371 (12.8%)    967 (16.7%)    

  **Baseline Comorbidities**                                                                                                                

  CCI                           2.8 ± 1.6          2.1 ± 1.5         2.4 ± 1.6       \<0.001   2.4 ± 1.6      2.4 ± 1.6      2.4 ± 1.6      0.29

  Myocardial infarction         22 (0.5%)          27 (0.5%)         37 (0.4%)       0.31      12 (0.4%)      10 (0.4%)      22 (0.4%)      0.91

  Congestive heart failure      287 (6.0%)         215 (4.1%)        457 (4.4%)      \<0.001   131 (4.5%)     136 (4.7%)     279 (4.8%)     0.91

  Peripheral vascular disease   26 (0.5%)          34 (0.6%)         54 (0.5%)       0.59      13 (0.5%)      17 (0.6%)      39 (0.7%)      0.47

  Cerebrovascular disease       284 (5.9%)         335 (6.3%)        629 (6.0%)      0.62      175 (6.0%)     173 (6.0%)     345 (6.0%)     0.94

  Dementia                      24 (0.5%)          74 (1.4%)         68 (0.7%)       \<0.001   20 (0.7%)      19 (0.7%)      35 (0.6%)      0.85

  COPD                          333 (6.9%)         362 (6.9%)        640 (6.1%)      0.08      179 (6.2%)     209 (7.2%)     414 (7.2%)     0.23

  Rheumatologic disease         47 (1.0%)          61 (1.2%)         103 (1.0%)      0.57      30 (1.0%)      28 (1.0%)      69 (1.2%)      0.66

  Peptic ulcer disease          403 (8.4%)         350 (6.6%)        691 (6.6%)      \<0.001   205 (7.1%)     207 (7.2%)     450 (7.8%)     0.55

  Hemiplegia or paraplegia      10 (0.2%)          20 (0.4%)         25 (0.2%)       0.18      8 (0.3%)       9 (0.3%)       13 (0.2%)      0.71

  CKD                           2396 (49.8%)       1063 (20.1%)      3225 (30.9%)    \<0.001   1005 (34.7%)   932 (32.2%)    1910 (33.0%)   0.06

  Liver disease ^a^             178 (3.7%)         204 (3.9%)        355 (3.4%)      0.30      96 (3.3%)      99 (3.4%)      192 (3.3%)     0.93

  Tumor                         86 (1.8%)          137 (2.6%)        195 (1.9%)      0.004     62 (2.1%)      56 (1.9%)      113 (2.0%)     0.77

  Diabetes                      1254 (26.1%)       1186 (22.5%)      2653 (25.4%)    \<0.001   687 (23.7%)    708 (24.5%)    1504 (26.0%)   0.16

  **CHA2DS2-VASc †**                                                                 \<0.001                                                \<0.001

  0                             211 (4.4%)         706 (13.4%)       1018 (9.7%)               204 (7.1%)     200 (6.9%)     400 (6.9%)     

  1                             890 (18.5%)        996 (18.9%)       1979 (18.9%)              636 (22.0%)    631 (21.8%)    1125 (19.4%)   

  2                             1268 (26.4%)       976 (18.5%)       1908 (18.3%)              834 (28.8%)    613 (21.2%)    1144 (19.8%)   

  3                             885 (18.4%)        858 (16.2%)       1896 (18.1%)              534 (18.5%)    505 (17.4%)    1124 (19.4%)   

  4                             706 (14.7%)        683 (12.9%)       1462 (14.0%)              438 (15.1%)    410 (14.2%)    894 (15.4%)    

  5                             456 (9.5%)         483 (9.1%)        1123 (10.8%)              279 (9.6%)     307 (10.6%)    691 (11.9%)    

  6                             245 (5.1%)         350 (6.6%)        660 (6.3%)                194 (6.7%)     158 (5.5%)     306 (5.3%)     

  7                             120 (2.5%)         174 (3.3%)        296 (2.8%)                98 (3.4%)      91 (3.1%)      155 (2.7%)     

  8                             24 (0.5%)          50 (1.0%)         99 (1.0%)                 23 (0.8%)      27 (0.9%)      45 (0.8%)      

  9                             2 (0.04%)          7 (0.1%)          9 (0.1%)                  2 (0.1%)       3 (0.1%)       6 (0.1%)       
  ---------------------------------------------------------------------------------------------------------------------------------------------------

Note: Continuous variables were presented as a mean ± standard deviation, and statistically analyzed using one-way analysis of variance, while categorical variables were described as counts (percentages) and analyzed using Chi-squared tests. † denotes "before discharge"; ^a^ moderate or severe liver disease. \* Level 1, 2, 3 and 4 denote medical center, regional hospital, district hospital and local medical clinic, respectively; Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCI, Charlson Comorbidity Index; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease; Gr, group; MACE, major adverse cardiac event; NSAID, non-steroid anti-inflammatory drug; NTD, new Taiwan Dollar.
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###### 

Comparisons of the variables within one year following hospital discharge and outcomes among the three groups.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
                                        Before Matching\   After Matching\                                                                           
                                        *n* = 20,540       *n* = 11,680                                                                              
  ------------------------------------- ------------------ ----------------- -------------- ---------- -------------- --------------- -------------- ---------
  **Outpatient visits, times ^‡^**                                                          \< 0.001                                                 0.09

  0--5 visits                           4596 (95.6%)       4932 (93.3%)      9297 (89.0%)              2763 (95.4%)   2747 (94.9%)    5530 (95.5%)   

  6--10 visits                          121 (2.5%)         151 (2.9%)        450 (4.3%)                67 (2.3%)      74 (2.6%)       190 (3.3%)     

  11--15 visits                         66 (1.4%)          123 (2.3%)        479 (4.6%)                47 (1.6%)      50 (1.7%)       123 (2.1%)     

  \>15 visits                           24 (0.5%)          77 (1.5%)         224 (2.1%)                18 (0.6%)      24 (0.8%)       47 (0.8%)      

  **Medication for hypertension ^‡^**                                                                                                                

  Alpha-Blocker                         571 (11.9%)        629 (11.9%)       1000 (9.6%)    \<0.001    358 (12.4%)    341 (11.8%)     698 (12.1%)    0.74

  Beta-Blocker                          2000 (41.6%)       1898 (35.9%)      3904 (37.4%)   \<0.001    1129 (39.0%)   1143 (39.5%)    2369 (40.9%)   0.52

  Calcium-Channel Blocker               3006 (62.5%)       2610 (49.4%)      4986 (47.7%)   \<0.001    1614 (55.8%)   1630 (56.3%)    3360 (58.0%)   0.49

  Diuretic                              1707 (35.5%)       2485 (47.0%)      4168 (39.9%)   \<0.001    1193 (41.2%)   1231 (42.5%)    2522 (43.6%)   0.35

  ACEI/ARB                              1725 (35.9%)       1791 (33.9%)      4176 (40.0%)   \<0.001    1057 (36.5%)   1073 (37.1%)    2231 (38.5%)   0.44

  **Other Medication ^‡^**                                                                                                                           

  Anti-diabetic drugs                   1468 (30.5%)       1595 (30.2%)      3230 (30.9%)   0.57       849 (29.3%)    887 (30.6%)     1846 (31.9%)   0.16

  Aspirin                               411 (8.6%)         396 (7.5%)        1259 (12.1%)   \<0.001    246 (8.5%)     247 (8.5%)      517 (8.9%)     0.88

  Clopidogrel                           143 (3.0%)         291 (5.5%)        443 (4.2%)     \<0.001    104 (3.6%)     114 (3.9%)      212 (3.7%)     0.70

  Ticlopidine                           208 (4.33%)        117 (2.2%)        370 (3.5%)     \<0.001    85 (2.9%)      86 (3.0%)       194 (3.4%)     0.57

  Dipyridamole                          1059 (22.0%)       792 (15.0%)       2224 (21.3%)   \<0.001    538 (18.6%)    555 (19.2%)     1147 (19.8%)   0.61

  Nitrate                               868 (18.1%)        1050 (19.9%)      1262 (12.1%)   \<0.001    501 (17.3%)    524 (18.1%)     1053 (18.2%)   0.71

  Statin                                519 (10.8%)        628 (11.9%)       1524 (15.6%)   \<0.001    334 (11.5%)    355 (12.3%)     743 (12.8%)    0.35

  Proton pump inhibitor                 26 (0.5%)          57 (1.1%)         64 (0.6%)      0.001      24 (0.8%)      22 (0.8%)       42 (0.7%)      0.84

  NSAID                                 3062 (63.7%)       2832 (53.6%)      7863 (75.2%)   \<0.001    1811 (65.6%)   1833 (63.3%)    3707 (64.0%)   0.84

  H2-blocker                            1173 (24.4%)       1232 (23.3%)      2718 (26.0%)   \<0.001    692 (23.9%)    739 (25.5%)     1535 (26.5%)   0.09

  **Outcome ^‡‡^**                                                                                                                                   

  Atrial fibrillation                   384 (8.0%)         274 (5.2%)        759 (7.3%)     \<0.001    214 (7.4%)     149 (5.2%)      383 (6.6%)     0.002

  MACE                                  830 (17.3%)        617 (11.7%)       1449 (13.9%)   \<0.001    467 (16.1%)    333 (11.5%)     772 (13.3%)    \<0.001

  Ischemia Stroke                       1226 (25.5%)       824 (15.6%)       4195 (40.1%)   \<0.001    696 (24.0%)    481 (16.6%)     2286 (39.5%)   \<0.001

  Hemorrhage Stroke                     367 (7.6%)         229 (4.3%)        1176 (11.3%)   \<0.001    222 (7.7%)     140 (4.8%)      719 (13.7%)    \<0.001

  All stroke                            1399 (29.1%)       944 (17.9%)       4748 (45.4%)   \<0.001    802 (27.7%)    555 (19.2%)     2617 (45.2%)   \<0.001

  Advanced CKD                          988 (20.6%)        723 (13.7%)       702 (6.8%)     \<0.001    822 (28.4%)    482 (16.6%)     423 (7.3%)     \<0.001

  Mortality                             2486 (51.7%)       2204 (41.7%)      3025 (29.0%)   \<0.001    1482 (51.2%)   1188 (41.0 %)   1890 (32.6%)   \<0.001
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: Continuous variables were presented as a mean ± standard deviation, and statistically analyzed using one-way analysis of variance, while categorical variables were described as counts (percentages) and analyzed using Chi-squared tests. † denotes "before discharge"; ^‡^ denotes "within one year following hospital discharge"; ^‡‡^ denotes "follow-up until death or the end of the study (31 December 2010)"; Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; Gr, group; MACE, major adverse cardiac event; NSAID, non-steroid anti-inflammatory drug; NTD, new Taiwan dollar.
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###### 

Incidences and risks of atrial fibrillation development among the three groups.

                                     Atrial Fibrillation   Crude Risk   Adjusted Risk ^‡^   Adjusted Risk ^‡‡^                                    
  ---------------------------------- --------------------- ------------ ------------------- -------------------------- -------------------------- --------------------------
  Before propensity score-matching                                                                                                                
  non-AKI                            759                   81,186.67    0.94                ref                        ref                        ref
  AKI-recovery                       274                   24,007.06    1.14                1.08 (0.94--1.24)          1.16 (1.00--1.33)          1.15 (1.10--1.32)
  non-recovery                       384                   28,726.82    1.34                1.36 \*\*\* (1.20--1.54)   1.62 \*\*\* (1.43--1.83)   1.58 \*\*\* (1.39--1.80)
  After propensity score-matching                                                                                                                 
  non-AKI                            383                   45,562.79    0.84                ref                        ref                        ref
  AKI-recovery                       149                   13,462.42    1.11                1.18 (0.98--1.43)          1.33 \*\* (1.10--1.61)     1.30 \*\* (1.07--1.58)
  non-recovery                       214                   17,088.48    1.25                1.42 \*\*\* (1.20--1.68)   1.72 \*\*\* (1.45--2.03)   1.62 \*\*\* (1.36--1.94)

Note: Cox proportional hazard model was applied to exam the effect of dialysis-requiring AKI on subsequent atrial fibrillation development. ^§^ presented as "100 person-year". ^‡^ Adjusted for Charlson Comorbidity Index, age, and gender. ^‡‡^ Adjusted for Charlson Comorbidity Index, age, gender, and advanced chronic kidney disease (time-varying covariate). \*\* denotes *p*-value ≤ 0.01; \*\*\* denotes *p*-value ≤ 0.001. Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; Gr, group; HR, hazard ratio.
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###### 

Incidences and risks of major adverse events between patients with and without atrial fibrillation.

                                     AF    Non-AF      Crude Risk   Adjusted Risk ^‡^                                                
  ---------------------------------- ----- ----------- ------------ ------------------- ------------ ------ ------------------------ ------------------------
  Before propensity score-matching                                                                                                   
  MACE                               987   9230.59     10.69        2466                117,959.62   2.09   2.25 \*\* (2.03--2.49)   1.88 \*\* (1.70--2.09)
  Hemorrhagic stroke                 161   10,381.48   1.55         1611                121,543.88   1.33   1.20 \* (1.02--1.41)     1.24 \* (1.05--1.46)
  Ischemic stroke                    667   7077.34     9.42         5578                96,917.20    5.76   1.62 \*\* (1.49--1.75)   1.31 \*\* (1.21--1.42)
  Total stroke                       714   6867.78     10.40        6377                93,540.77    6.82   1.50 \*\* (1.39--1.62)   1.26 \*\* (1.17--1.36)
  After propensity score-matching                                                                                                    
  MACE                               511   4729.33     10.80        1337                67,595.80    1.98   2.49 \*\* (2.17--2.86)   2.11 \*\* (1.83--2.43)
  Hemorrhagic stroke                 89    5321.74     1.67         992                 68,827.18    1.44   1.20 (0.97--1.49)        1.23 (0.99--1.53)
  Ischemic stroke                    333   3766.11     8.84         3130                55,361.13    5.65   1.57 \*\* (1.40--1.75)   1.33 \*\* (1.19--1.49)
  All Stroke                         362   3654.72     9.90         3612                53,357.19    6.77   1.46 \*\* (1.31--1.63)   1.28 \*\* (1.15--1.43)

Note: Cox proportional hazard model was applied to exam the effect of dialysis-requiring AKI on subsequent atrial fibrillation development. ^§^ presented as "100 person-year". ^‡^ Adjusted to Charlson Comorbidity Index, age, and gender. \* denotes *p*-value ≤ 0.05; \*\* denotes *p*-value ≤ 0.001; Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; ESRD, end-stage renal disease; HR, hazard ratio; MACE, major adverse cardiac event.
